Carl Zeiss Meditec : achieves EBIT margin of 18.1% in fiscal year 2018/19
October 23, 2019 at 08:00 am EDT
Share
DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
23-Oct-2019 / 13:55 CET/CEST
Update of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
Jena, October 23, 2019
As already announced on October 2, 2019, Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 1,459 million in fiscal year 2018/19 (past year: EUR 1,280.9 million) and has significantly expanded EBIT[1] margin[2], exceeding the initial forecast of 15.0% to 17.5%. Based on today's new assessment, EBIT for fiscal year 2018/19 amounted to approx. EUR 264 million (past year: EUR 197.1 million), leading to an EBIT margin of 18.1%.
Upon publication of preliminary results on October 2, 2019, the company had anticipated a still higher EBIT margin for fiscal year 2018/19.
The shortfall was caused by higher operating expenses in the fourth quarter of fiscal year 2018/19, in part driven by the already announced higher investments in the fields of Surgical Ophthalmology and Digitalization.
Final results for fiscal year 2018/19 will be provided on December 6, 2019.
Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com
[1] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2017/18, p. 76 for reconciliation). [2] Calculation: EBIT margin = EBIT / revenue (in %) (see Annual Report 2017/18, p. 76).
23-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone:
+49 (0)3641 220-0
Fax:
+49 (0)3641 220-112
E-mail:
investors.meditec@zeiss.com
Internet:
www.zeiss.de/meditec-ag/ir
ISIN:
DE0005313704
WKN:
531370
Indices:
MDAX, TecDAX
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.